Starpharma Holdings Ltd has released a press release.
Starpharma signs new DEP agreement with MSD
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Quarterly Activities Report & Appendix 4C
- VIRALEZE Protects Against Omicron in Viral Challenge Model
- VIRALEZE relaunched by LloydsPharmacy in the UK
- SPL signs expanded DEP research agreement with US Biopharma
- SPL7013 in VIRALEZE virucidal against influenza A and B
Later from Starpharma
- Starpharma annual report and full year financial results
- S&P DJI Announces September 2022 Quarterly Rebalance
- New clinical data for DEP cabazitaxel in prostate cancer
- VIRALEZE distribution agreement for Hong Kong and Macau
- AGM Chairman address and CEO presentation
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma